Evidence map›Paper›PMID 33520943›Full record

ArticleFrontiers in chemistry2020

Simone Di Micco, Simona Musella, Maria C Scala, Marina Sala, Pietro Campiglia, Giuseppe Bifulco, Alessio Fasano

Open access · goldAbstract read
In one paragraph

Article in Frontiers in chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Exploring new catechin derivatives as SARS-CoV-2 MComputers in biology and medicine · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Phytochemicals ofFrontiers in molecular biosciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Simone Di MiccoEuropean Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy.
Simona MusellaEuropean Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy.
Maria C ScalaDepartment of Pharmacy, University of Salerno, Salerno, Italy.
Marina SalaDepartment of Pharmacy, University of Salerno, Salerno, Italy.
Pietro CampigliaEuropean Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy.
Giuseppe BifulcoDepartment of Pharmacy, University of Salerno, Salerno, Italy.
Alessio FasanoEuropean Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy.
University of Salerno · ITEuropean Biomedical Research Institute of Salerno · IT

Funding

Microbiome-derived Metabolites Linked to Celiac Disease Onset in Infants at RiskR01DK104344 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI FASANO, ALESSIO · 2016 to 2020
$3.4M
NIDDK NIH HHS R01 DK104344
6 · The paper itself

Abstract

The most severe outcome of COVID-19 infection is the development of interstitial pneumonia causing acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS), both responsible for the infected patients' mortality. ALI and ARDS are characterized by a leakage of plasma components into the lungs, compromising their ability to expand and optimally engage in gas exchange with blood, resulting in respiratory failure. We have previously reported that zonulin, a protein dictating epithelial and endothelial permeability in several districts, including the airways, is involved in ALI pathogenesis in mouse models, and that its peptide inhibitor Larazotide acetate (also called AT1001) ameliorated ALI and subsequent mortality by decreasing mucosal permeability to fluid and extravasation of neutrophils into the lungs. With the recent crystallographic resolution of the SARS-CoV-2 main protease (M

Indexed as

drug repurposingMM-GBSAmolecular dockingmolecular dynamicsMpro inhibitor

Identifiers

PMID33520943
PMCPMC7843458
OpenAlexW3118383420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.